Ask the Doctors: February 2017

Chronic use of NSAIDs is common in arthritis patients. In 2015, the FDA strengthened a warning about the potential heart hazards of over-the-counter (OTC) NSAIDs. Selective COX-2 inhibitors, such as celecoxib (Celebrex), were developed in the hope of reducing gastrointestinal (GI) toxicity and still maintaining an anti-inflammatory effect. You refer to a recent study called PRECISION, designed after the withdrawal of the COX-2 inhibitor Vioxx due to an unfavorable CVD profile.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access